AR024566A1 - Administracion de esteroides androgenicos no orales a mujeres - Google Patents

Administracion de esteroides androgenicos no orales a mujeres

Info

Publication number
AR024566A1
AR024566A1 ARP000102889A ARP000102889A AR024566A1 AR 024566 A1 AR024566 A1 AR 024566A1 AR P000102889 A ARP000102889 A AR P000102889A AR P000102889 A ARP000102889 A AR P000102889A AR 024566 A1 AR024566 A1 AR 024566A1
Authority
AR
Argentina
Prior art keywords
women
administration
effective amount
estrogen
oral androgen
Prior art date
Application number
ARP000102889A
Other languages
English (en)
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of AR024566A1 publication Critical patent/AR024566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones, métodos y equipos para mejorar la salud en una mujer que tiene niveles elevados de SHBG,o quien está recibiendo suplemento oral de estrogenoadministrando de forma no oral una cantidad efectiva de un esteroide androgénico.Adicionalment e, se proporcionan composiciones, métodos y equipos para laco-administracion de una cantidad efectiva de un estrogeno administrado oralmente y una cantidad efectiva de un esteroide androgénico administrado de forma nooral para mujeresque necesitan d el suplemento de estrogeno.
ARP000102889A 1999-06-11 2000-06-12 Administracion de esteroides androgenicos no orales a mujeres AR024566A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13885499P 1999-06-11 1999-06-11
US13885199P 1999-06-11 1999-06-11
US13932399P 1999-06-11 1999-06-11

Publications (1)

Publication Number Publication Date
AR024566A1 true AR024566A1 (es) 2002-10-16

Family

ID=27385240

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102889A AR024566A1 (es) 1999-06-11 2000-06-12 Administracion de esteroides androgenicos no orales a mujeres

Country Status (25)

Country Link
US (3) US6583129B1 (es)
EP (1) EP1189619A4 (es)
JP (2) JP5184727B2 (es)
KR (2) KR20070063609A (es)
CN (1) CN1220491C (es)
AR (1) AR024566A1 (es)
AU (1) AU775145B2 (es)
BR (1) BR0011740A (es)
CA (1) CA2376797C (es)
CO (1) CO5180583A1 (es)
CZ (1) CZ299198B6 (es)
HK (1) HK1048269B (es)
HU (1) HUP0301813A2 (es)
IL (1) IL147010A0 (es)
MX (1) MXPA01012769A (es)
MY (1) MY126960A (es)
NO (1) NO20016046L (es)
NZ (1) NZ516502A (es)
PE (1) PE20010404A1 (es)
PL (1) PL352250A1 (es)
SA (1) SA00210404B1 (es)
SK (1) SK18212001A3 (es)
TR (1) TR200200406T2 (es)
TW (1) TWI281398B (es)
WO (1) WO2000076522A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
CA2376797C (en) * 1999-06-11 2011-03-22 Watson Pharmaceuticals, Inc. Administration of non oral androgenic steroids to women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020151530A1 (en) * 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
KR100851648B1 (ko) * 2001-07-09 2008-08-13 레프로스 쎄라피우틱스 아이엔씨. 남성의 테스토스테론 결핍치료용 물질
US20030109508A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
JP2005512995A (ja) * 2001-11-09 2005-05-12 ファイザー ヘルス アーベー 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト
US20140212508A1 (en) * 2001-12-20 2014-07-31 John Wayne Kennedy Copper/zinc superoxide dismutase (sod) formulation for the treatment of traumas including amyotropic lateral sclerosis
US20030216366A1 (en) * 2002-04-03 2003-11-20 Leonard Thomas W. Step-down estrogen therapy
EP1350541A1 (de) * 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Verwendung von einem Dehydroepiandrosteron und einem Estradiol Derivat zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung klimakterischer Beschwerden in der Postmenopause
AU2003221715A1 (en) * 2002-06-14 2003-12-31 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat vaginal dryness
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
CA2527175A1 (en) * 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
EP1530965B1 (en) 2003-11-11 2006-03-08 Mattern, Udo Controlled release delivery system of sexual hormones for nasal application
BRPI0513129A (pt) * 2004-07-14 2008-04-29 Repros Therapeutics Inc método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo
ES2553101T3 (es) 2004-10-20 2015-12-04 Endorecherche Inc. Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas
US20150005360A1 (en) 2004-10-25 2015-01-01 Nse Products, Inc. Phytoestrogen compositions and associated methods
JP2008530016A (ja) * 2005-02-04 2008-08-07 リプロス セラピューティクス インコーポレイテッド 雄性不妊症の処置のためのトランス−クロミフェンを用いる方法およびトランス−クロミフェンを含む物質
CN101252936A (zh) * 2005-03-02 2008-08-27 奈森特医药公司 眼用组合物的药学可接受的载体
JP5785680B2 (ja) * 2005-03-22 2015-09-30 リプロス セラピューティクス インコーポレイテッド トランス−クロミフェン用の投与レジメン
WO2007012815A1 (en) * 2005-07-27 2007-02-01 Ingenia Technology Limited Authenticity verification
GB0523550D0 (en) * 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
US20080015170A1 (en) * 2005-12-01 2008-01-17 The Procter & Gamble Company Method of treating menopausal women transdermally with testosterone
CA2654152A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US20080045486A1 (en) * 2006-08-17 2008-02-21 Tang-Liu Diane D S Ocular administration of testosterone
KR101307133B1 (ko) 2006-10-04 2013-09-12 엠엔피 페이턴트 악티엔게젤샤프트 신경전달물질의 비강 투여를 위한 서방형 전달 시스템
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CN101896174B (zh) 2007-10-16 2012-10-31 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
WO2009142699A1 (en) * 2008-05-19 2009-11-26 The Procter & Gamble Company Treatment of heart failure in women
US9572817B2 (en) * 2008-07-04 2017-02-21 The Heart Research Institute Ltd. Use of androgens for vascular regeneration and endothelial repair
US8658628B2 (en) * 2009-06-18 2014-02-25 Karan Y. Baucom Hormone delivery system and method
US9795617B2 (en) 2009-06-18 2017-10-24 Baucom Institute for Longevity and Life Enhancement, Inc. Hormone delivery system and method
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130231317A1 (en) * 2011-07-19 2013-09-05 Michael S. Riepl Dhea bioadhesive controlled release gel
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9687458B2 (en) 2012-11-02 2017-06-27 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
EP2934559A4 (en) * 2012-12-05 2016-07-20 Ge Nutrients Inc USE OF A BOCKSHORNKLEE EXTRACT FOR REINFORCING THE FEMALE LIBIDO
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2968365A1 (en) * 2013-03-15 2016-01-20 Malhotra, Raman Systemic administration of androgen in treating dry eye syndrome
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11523994B2 (en) 2018-01-10 2022-12-13 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
BE1027858B1 (fr) * 2019-12-13 2021-07-14 Georges Debled Composition pharmaceutique pour la contraception chez la femme
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
US4210664A (en) 1979-03-02 1980-07-01 Merrell Toraude Et Compagnie Use of α,α'-dithiobis(β-arylacrylic acid) derivatives to enhance zinc serum and tissue concentrations
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
DK0462189T3 (da) * 1989-03-10 1995-11-20 Endorecherche Inc Kombinationsterapi til behandling af østrogenfølsomme sygdomme
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
DE69433994T2 (de) * 1993-01-19 2005-09-22 Endorecherche Inc., Ste-Foy Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
TR200100063T2 (tr) 1998-06-11 2001-05-21 Endorecherche, Inc Androst-5-en-3ß,17ß-diol için farmasötik kompozisyonlar ve kullanımlar
CA2376797C (en) * 1999-06-11 2011-03-22 Watson Pharmaceuticals, Inc. Administration of non oral androgenic steroids to women

Also Published As

Publication number Publication date
NZ516502A (en) 2004-03-26
US20070190120A1 (en) 2007-08-16
KR20070063609A (ko) 2007-06-19
US8551516B2 (en) 2013-10-08
BR0011740A (pt) 2002-05-14
NO20016046D0 (no) 2001-12-11
WO2000076522A1 (en) 2000-12-21
CZ20014499A3 (cs) 2002-05-15
SK18212001A3 (sk) 2002-04-04
IL147010A0 (en) 2002-08-14
AU5475800A (en) 2001-01-02
PL352250A1 (en) 2003-08-11
JP2013049682A (ja) 2013-03-14
US20030153540A1 (en) 2003-08-14
PE20010404A1 (es) 2001-04-09
HK1048269B (zh) 2006-01-13
HK1048269A1 (en) 2003-03-28
CO5180583A1 (es) 2002-07-30
MXPA01012769A (es) 2003-06-24
AU775145B2 (en) 2004-07-22
TR200200406T2 (tr) 2002-06-21
US7186706B2 (en) 2007-03-06
JP5184727B2 (ja) 2013-04-17
CN1220491C (zh) 2005-09-28
US6583129B1 (en) 2003-06-24
HUP0301813A2 (hu) 2003-09-29
TWI281398B (en) 2007-05-21
CN1367698A (zh) 2002-09-04
JP2003505345A (ja) 2003-02-12
KR20020011437A (ko) 2002-02-08
SA00210404B1 (ar) 2006-08-21
NO20016046L (no) 2002-02-06
EP1189619A4 (en) 2004-06-09
CA2376797A1 (en) 2000-12-21
CZ299198B6 (cs) 2008-05-14
EP1189619A1 (en) 2002-03-27
MY126960A (en) 2006-11-30
CA2376797C (en) 2011-03-22

Similar Documents

Publication Publication Date Title
AR024566A1 (es) Administracion de esteroides androgenicos no orales a mujeres
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
AR028809A1 (es) Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica
HK1050839A1 (en) Use of pharmaceutical compositions comprising oxcarbazepine in the fasted state
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
AR073972A2 (es) Composiciones farmaceuticas para el tratamiento de carencias estrogenicas en la menopausia y para la prevencion de la osteoporosis en mujeres menopausicas
NO20061937L (no) Utvidet trefaseprevansjonskur
ATE301129T1 (de) Androgen glykoside und die androgenische aktivität davon
SG154323A1 (en) Estrogen replacement therapy
MXPA02004084A (es) Nueva composicion hormonal y su utilizacion.
BR0111051A (pt) Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente
EA200900829A1 (ru) Фармацевтический препарат для уменьшения эндометриоза
AR039547A1 (es) Terapia de reemplazo hormonal
NO20072687L (no) Farmasoytisk prevensjonspreparat
JP2003522795A5 (es)
AR039227A1 (es) Terapia de reemplazo hormonal
AR022852A1 (es) Nuevos androgenos
AR039477A1 (es) Terapia de reemplazo hormonal
AR033260A1 (es) Nueva composicion hormonal y su utilizacion
SI1937274T1 (sl) Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
RU2006126632A (ru) Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль
PE20011051A1 (es) Composiciones que comprenden estrogeno y drospirenona micronizada
ZA200110181B (en) Administration of non-oral androgenic steroids to women.

Legal Events

Date Code Title Description
FB Suspension of granting procedure